高脂血症又被称作血脂代谢异常,其内涵包括甘油三酯升高、总胆固醇升高、低密度脂蛋白胆固醇升高和高密度脂 蛋白胆固醇降低,脂代谢异常是恶性肿瘤患者最重要的代谢改变之一,这可能与恶性肿瘤的发生、发展、转移和预后密切相 关。 高脂血症与恶性肿瘤的关系尚未阐述清楚,有文献报道高脂血症是恶性肿瘤的危险因素,对其生存预后产生不良影响。 也有学者认为总胆固醇升高是肿瘤的保护因素,并且与肿瘤患者的总死亡率下降相关。 目前对于肿瘤的血脂管理,国际上并 没有确切的指导意见,大量的文献研究结果认为血脂异常与肿瘤的关系非常复杂。 脂质是生物膜和细胞结构重要组成部分。 脂质用于能量储存和代谢,并作为许多细胞活动的信号分子发挥重要作用。 脂质在恶性肿瘤中的分子生物学机制更加复杂。 本文将基于常见恶性肿瘤患者营养状况与临床结局相关性研究(INSCOC)结果并且结合国内外文献报道做系统综述,进一步 阐述高脂血症与恶性肿瘤相关性。

Hyperlipidemia also known as dyslipidemia includes elevated triglycerides elevated total cholesterol elevated low-density lipoprotein cholesterol and decreased high-density lipoprotein cholesterol. Abnormal lipid metabolism is one of the most important metabolic changes in patients with malignant tumors which may be closely related to the occurrence development metastasis and prognosis of malignant tumors. The relationship between hyperlipidemia and malignant tumors has not been clearly elucidated. There are literature reports that hyperlipidemia is a risk factor for malignant tumors and has a negative impact on their survival prognosis. Some scholars also believe that elevated total cholesterol is a protective factor against cancer and is associated with a decrease in overall mortality rate among cancer patients. At present there is no precise guidance on blood lipid management for cancer internationally and a large number of literature research results suggest that the relationship between abnormal blood lipids and cancer is very complex. Lipids are important components of biological membranes and cellular structures. Lipids are used for energy storage and metabolism and play an important role as signaling molecules for many cellular activities. The molecular biology mechanism of lipids in malignant tumors may be more complex. This article will be based on the research results of the Investigation of the Nutrition Status and Clinical Outcome of Common Cancers INSCOC trial and combined with domestic and foreign literature reports to provide a systematic review further elaborating on the correlation between hyperlipidemia and malignant tumors.